Literature DB >> 7523009

Analysis of idiotope structure of ovarian cancer antibodies: recognition of the same epitope by two monoclonal antibodies differing mainly in their heavy chain variable sequences.

R Slobbe1, L Poels, G ten Dam, O Boerman, L Nieland, J Leunissen, F Ramaekers, G van Eys.   

Abstract

Two MoAbs, independently raised against ovarian carcinoma cells and referred to as OV-TL3 and OV-TL16, display an identical reaction pattern with a membrane-associated protein in both normal and malignant ovarian cells. Also, a similar binding affinity constant and a similar number of binding sites per cell indicate that both MoAbs bind to the same antigen. Competition assays reveal that OV-TL16 is able to compete with OV-TL3 for binding to OVCAR-3 cells. Epitope mapping using a filamentous phage hexapeptide epitope library showed that both MoAbs are able to select identical phages, suggesting that their epitopes are identical or at least overlapping. However, purified polyclonal and monoclonal anti-idiotypic antibodies directed against OV-TL3 failed to recognize the OV-TL16 idiotype, indicating that the structure of the antigen-binding regions of both antibodies is distinct. This was corroborated by molecular cloning and sequencing of the variable heavy (VH) and light (VL) chain immunoglobulin regions of both MoAbs. The VH regions of both antibodies were found to be distinct, whereas the VL regions are almost identical. Computer modelling of the idiotypes suggests that the complementarity determining regions (CDR), with the exception of VHCDR3, have (almost) identical spatial configurations. Our data indicate that, although structurally different in their VH regions, OV-TL3 and OV-TL16 are able to bind to identical epitopic regions on the antigen, because differences in primary structure do not exclude the formation of sufficient and similar spatial structures for the interaction with an epitope.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523009      PMCID: PMC1534177          DOI: 10.1111/j.1365-2249.1994.tb06613.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Structure of antibody hypervariable loops reproduced by a conformational search algorithm.

Authors:  R E Bruccoleri; E Haber; J Novotný
Journal:  Nature       Date:  1988-10-06       Impact factor: 49.962

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Europium as a label in time-resolved immunofluorometric assays.

Authors:  I Hemmilä; S Dakubu; V M Mukkala; H Siitari; T Lövgren
Journal:  Anal Biochem       Date:  1984-03       Impact factor: 3.365

5.  Monoclonal antibody against human ovarian tumor-associated antigens.

Authors:  L G Poels; D Peters; Y van Megen; G P Vooijs; R N Verheyen; A Willemen; C C van Niekerk; P H Jap; G Mungyer; P Kenemans
Journal:  J Natl Cancer Inst       Date:  1986-05       Impact factor: 13.506

6.  Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors.

Authors:  T C Hamilton; R C Young; W M McKoy; K R Grotzinger; J A Green; E W Chu; J Whang-Peng; A M Rogan; W R Green; R F Ozols
Journal:  Cancer Res       Date:  1983-11       Impact factor: 12.701

7.  Antibody-selectable filamentous fd phage vectors: affinity purification of target genes.

Authors:  S F Parmley; G P Smith
Journal:  Gene       Date:  1988-12-20       Impact factor: 3.688

8.  Monoclonal antibodies against ovarian carcinoma-associated antigens, raised by immunization with cyst fluids.

Authors:  O Boerman; K Makkink; L Massuger; C Thomas; P Kenemans; T Hanselaar; L Poels
Journal:  Anticancer Res       Date:  1989 May-Jun       Impact factor: 2.480

9.  Different VL and VH germ-line genes are used to produce similar combining sites with specificity for alpha(1----6)dextrans.

Authors:  P N Akolkar; S K Sikder; S B Bhattacharya; J Liao; F Gruezo; S L Morrison; E A Kabat
Journal:  J Immunol       Date:  1987-06-15       Impact factor: 5.422

10.  Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity.

Authors:  S Miotti; S Canevari; S Ménard; D Mezzanzanica; G Porro; S M Pupa; M Regazzoni; E Tagliabue; M I Colnaghi
Journal:  Int J Cancer       Date:  1987-03-15       Impact factor: 7.396

View more
  1 in total

1.  Combination chemotherapy and photodynamic therapy with fab' fragment targeted HPMA copolymer conjugates in human ovarian carcinoma cells.

Authors:  Jarunee Hongrapipat; Pavla Kopecková; Jihua Liu; Sompol Prakongpan; Jindrich Kopecek
Journal:  Mol Pharm       Date:  2008-08-27       Impact factor: 4.939

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.